GLP-1 is a hormone your gut releases after you eat; GLP-1 medications copy parts of its signal to help manage blood sugar, appetite and, when a medicine is approved for that purpose, body weight.
People use “GLP-1” to mean the natural hormone, a family of medicines and sometimes any popular weight-management injection. Those ideas are related, but not identical.
This page explains the difference without telling you which medicine to take. A doctor, GP or other qualified prescriber should assess whether a medication is appropriate for you, using your health history, other medicines and the official prescribing information.
What does GLP-1 mean?
GLP-1 stands for glucagon-like peptide-1. It is an incretin hormone: one of the chemical messages released from your digestive system when food arrives.
Natural GLP-1 does not “burn fat.” It helps coordinate what happens after a meal. As described by Daniel Drucker in Cell Metabolism and by the US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), it signals the pancreas and brain and affects digestion. Your body breaks it down quickly.
GLP-1 receptor agonist medicines are designed to activate the same receptor for much longer. “Agonist” simply means something that switches a receptor on. This longer-lasting signal can improve blood sugar control and reduce appetite for some people.
How do GLP-1 medications work?
The effect is a combination of signals rather than one appetite “off switch.”
| Signal or organ | What the medication does | Why it may matter |
|---|---|---|
| Pancreas | Encourages insulin release when blood glucose is elevated | Helps lower blood glucose after food |
| Liver and pancreas | Reduces inappropriate glucagon signaling | Helps prevent the liver releasing more glucose when it is not needed |
| Brain | Acts on appetite and fullness pathways | Hunger, cravings or persistent thoughts about food may lessen |
| Stomach and digestive system | Can slow stomach emptying, particularly after treatment begins | Fullness may arrive sooner and last longer; digestive side effects can also occur |
Responses vary. A quieter appetite can make eating less feel easier, but the medicine does not choose nutritious food, preserve muscle automatically or replace medical follow-up.
Which medicines do people mean when they say “GLP-1”?
Semaglutide and tirzepatide are the names most beginners encounter. The generic name identifies the active ingredient; the brand identifies a product and approved use.
| Active ingredient | Medicine type | Common US brand context | Common UK brand context |
|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Ozempic for type 2 diabetes; Wegovy for chronic weight management; Rybelsus oral tablet for type 2 diabetes | Ozempic for type 2 diabetes; Wegovy for weight management; Rybelsus oral tablet for type 2 diabetes |
| Tirzepatide | Dual GIP and GLP-1 receptor agonist | Mounjaro for type 2 diabetes; Zepbound for chronic weight management | Mounjaro is the familiar brand for type 2 diabetes and weight management |
| Liraglutide | GLP-1 receptor agonist | Liraglutide (formerly sold as Victoza; now available as a generic) for type 2 diabetes; Saxenda for weight management | Victoza for type 2 diabetes; Saxenda for weight management |
| Dulaglutide | GLP-1 receptor agonist | Trulicity for type 2 diabetes | Trulicity for type 2 diabetes |
Most products in this table are injections, but semaglutide is also available as the oral tablet Rybelsus for type 2 diabetes.
The table describes broad regulatory uses, not personal eligibility, current supply or what any service will prescribe. Authorizations, access routes and local criteria can change. In the US, the Food and Drug Administration (FDA) label is the source of truth for an approved use. In the UK, check current Medicines and Healthcare products Regulatory Agency information and NHS or National Institute for Health and Care Excellence (NICE) guidance with your GP or prescriber.
Is tirzepatide really a GLP-1 medication?
In everyday conversation, yes. More precisely, tirzepatide is a dual GIP/GLP-1 receptor agonist: it activates receptors for both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. Semaglutide activates the GLP-1 receptor.
That difference matters when comparing evidence and safety information; it does not make either medicine automatically right for a person. FDA-approved prescribing information and NHS England guidance place both within broader care that includes nutrition, activity and monitoring.
Are Ozempic and Wegovy the same thing?
They contain the same active ingredient, semaglutide, but they are distinct branded products with different approved purposes and prescribing information. In the US and UK, Ozempic is associated with type 2 diabetes, while Wegovy is the semaglutide brand for weight management.
The same principle applies to tirzepatide: in the US, Mounjaro is the diabetes brand and Zepbound is the weight-management brand; in the UK, Mounjaro is used in both contexts. Ask a pharmacist or prescriber about the exact product on your prescription.
What can GLP-1 medicines help with?
Depending on the product and person, these medicines may:
- improve blood glucose control in type 2 diabetes;
- reduce hunger and energy intake;
- support clinically meaningful weight loss when prescribed for weight management; and
- provide additional benefits proven for particular drugs and patient groups, such as reducing certain cardiovascular risks.
Benefits are medicine- and indication-specific, not promises attached to every drug called a GLP-1. FDA labels state which risk-reduction claims have enough evidence for each product.
These are treatments for chronic health conditions, not a verdict on willpower or a shortcut someone has to “earn.” A prescription does not guarantee a particular weight change.
What side effects and risks should a beginner know about?
Digestive effects are the most common. The exact warnings differ by product, so this overview cannot replace the patient leaflet or a conversation with your prescriber.
| Type | Examples described in official prescribing information | What to do |
|---|---|---|
| Common digestive effects | Nausea, diarrhea, vomiting, constipation, abdominal discomfort or indigestion | Tell your prescriber if symptoms are troublesome, persistent or make it difficult to eat or drink |
| Dehydration concern | Fluid loss after ongoing vomiting or diarrhea, sometimes linked with kidney problems | Contact your healthcare team promptly if you cannot keep fluids down or show signs of dehydration |
| Urgent symptoms | Severe or persistent abdominal pain, a severe allergic reaction or symptoms of a serious gallbladder problem | Seek urgent medical assessment rather than trying to diagnose or manage it from an article |
| Low blood glucose | Risk can be higher when some GLP-1 medicines are used with insulin or medicines that stimulate insulin release | Ask your diabetes team how to recognize and manage low blood glucose with your prescribed combination |
US prescribing information for semaglutide and tirzepatide products includes a boxed warning about thyroid C-cell tumors seen in rodents and explains who should not use them. Pancreatitis, gallbladder disease, pregnancy plans, diabetic eye disease, kidney or digestive problems and all other medicines belong in the prescriber conversation. Tell your surgical or anesthesia team that you use a GLP-1 medicine before a planned procedure because delayed stomach emptying may affect preparation.
The name “semaglutide” or “tirzepatide” alone does not confirm that a product is approved, authentic or suitable for you. Copying another person’s plan or buying outside a legitimate prescription and pharmacy can be dangerous.
Why does food still matter on a GLP-1 medication?
A reduced appetite does not remove your need for protein, vitamins, minerals, fiber and fluids. With less interest in food, each meal may need to do more useful work.
Start with the basics your own care team has approved:
- include a protein-rich food at meals to support muscle;
- choose fruit, vegetables, whole grains or other fiber-containing foods you tolerate;
- drink regularly, especially if digestive symptoms reduce your intake;
- eat slowly and notice whether large, rich or very fatty meals feel uncomfortable; and
- include strength-building activity if it is safe for you.
Our practical guide to what to eat on Mounjaro turns those principles into meal ideas. The broader GLP-1 diet guide explains why there is no special branded diet, while protein and muscle on GLP-1 medication covers the part that appetite suppression can make easy to miss.
Weight loss from any method can include lean tissue as well as fat. A systematic review by Chaston, Dixon and O’Brien in the International Journal of Obesity found that the composition varies. Support your nutrition and muscle; do not force food through significant symptoms. If eating or drinking is difficult, contact your doctor, GP, dietitian or prescriber.
What should you ask your doctor, GP or prescriber?
Bring a complete list of your medicines and supplements, then ask:
- What condition is this exact product intended to treat for me?
- Which benefits are supported for someone with my health history?
- Which common and serious side effects should I watch for?
- Could it interact with my diabetes medicines or affect how other oral medicines are absorbed?
- Who should I contact if I cannot eat, drink or manage symptoms?
- What nutrition, activity and monitoring support is available?
The useful question is not “Which injection is best?” It is “What are the likely benefits, risks and practical demands of this exact option for me?”
One clear next step: If you already have a prescription and want calm, food-first structure, explore The GLP-1 Companion—a $9.99 guide to meals, protein and muscle-supporting habits. It provides education, not medication or dosing advice.
FAQ
Is GLP-1 a hormone or a medication?
Both uses are common. GLP-1 is a natural gut hormone. A GLP-1 receptor agonist is a medicine designed to activate the hormone’s receptor for longer. Tirzepatide also activates the GIP receptor, so it is more precisely a dual GIP/GLP-1 medicine.
Is insulin a GLP-1?
No. Insulin and GLP-1 are different hormones. GLP-1 signaling can encourage the pancreas to release insulin when blood glucose is elevated, but a GLP-1 medicine is not insulin.
Are all GLP-1 medications for weight loss?
No. Some are approved for type 2 diabetes, some for chronic weight management and some brands have additional approved uses. The active ingredient, brand, country and official label all matter.
Does a GLP-1 medication melt or burn fat?
No. Its appetite effects can help a person consume less energy, which can lead to weight loss over time. The medication does not selectively melt fat, and weight change can include both fat and lean tissue.
What is the difference between semaglutide and tirzepatide?
Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors. They are different medicines with different labels, evidence and safety information; a prescriber should compare them in the context of your health rather than by brand popularity.
Who can tell me whether a GLP-1 medicine is appropriate?
A qualified doctor, GP or other regulated prescriber who can review your diagnoses, medical history and current medicines. A pharmacist can also explain the exact product, its leaflet and potential interactions.
Written by Ricky Valentine · Last updated 31 August 2026
Citations to verify in edit pass: US Food and Drug Administration, current Prescribing Information for Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide), Mounjaro (tirzepatide) and Zepbound (tirzepatide); verify the end-2024 US Victoza discontinuation and current generic liraglutide availability; FDA, “FDA Approves New Medication for Chronic Weight Management” (November 8, 2023); National Institute of Diabetes and Digestive and Kidney Diseases, “Prescription Medications to Treat Overweight & Obesity”; NHS England, “Weight management injections”; NICE Technology Appraisal TA1026, “Tirzepatide for managing overweight and obesity”; Medicines and Healthcare products Regulatory Agency, “GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation” (Drug Safety Update, January 2025) and “MHRA updates guidance for GLP-1 prescribers and patients” (January 29, 2026); Drucker DJ, “Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1,” Cell Metabolism (2018); Chaston TB, Dixon JB and O’Brien PE, “Changes in fat-free mass during significant weight loss: a systematic review,” International Journal of Obesity (2007).